Enlivex Therapeutics Trial Continues After Positive DSMB Review
Ticker: ENLV · Form: 6-K · Filed: Sep 24, 2024 · CIK: 1596812
Sentiment: bullish
Topics: clinical-trial, drug-development, covid-19
TL;DR
Enlivex's COVID-19 trial gets green light from safety board, trial continues as planned.
AI Summary
On September 24, 2024, Enlivex Therapeutics Ltd. announced that the independent Data and Safety Monitoring Board (DSMB) completed an interim data review for its Phase II clinical trial of Allocetra in patients with severe COVID-19. The DSMB recommended that the trial continue without modification, indicating positive safety and efficacy signals.
Why It Matters
This positive interim review by the DSMB suggests the trial is progressing well and could lead to further positive developments for Enlivex's lead drug candidate, Allocetra.
Risk Assessment
Risk Level: medium — Clinical trial results are inherently uncertain, and while the DSMB review is positive, the ultimate success of the trial and drug approval remains to be seen.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- Data and Safety Monitoring Board (company) — Independent review board
- Allocetra (drug) — Drug candidate being tested
- September 24, 2024 (date) — Date of announcement
FAQ
What was the purpose of the Data and Safety Monitoring Board's review?
The DSMB conducted an interim data review of Enlivex's Phase II clinical trial of Allocetra in patients with severe COVID-19.
What was the outcome of the DSMB's review?
The DSMB recommended that the trial continue without modification.
What drug is being tested in the Phase II clinical trial?
The drug being tested is Allocetra.
What condition is the Phase II trial focused on?
The trial is focused on patients with severe COVID-19.
When was this announcement made?
The announcement was made on September 24, 2024.
Filing Stats: 240 words · 1 min read · ~1 pages · Grade level 11.5 · Accepted 2024-09-24 08:33:16
Filing Documents
- ea021541001-6k_enlivex.htm (6-K) — 9KB
- ea021541001ex99-1_enlivex.htm (EX-99.1) — 10KB
- image_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-081211.txt ( ) — 23KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Enlivex Therapeutics Ltd. (Registrant) By: /s/ Oren Hershkovitz Name: Title: Oren Hershkovitz Chief Executive Officer Date: September 24, 2024